IBI 130
Alternative Names: IBI-130Latest Information Update: 06 Dec 2023
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 14 Nov 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (Parenteral) (NCT05923008)
- 28 Jun 2023 Innovent Biologics plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Australia (Parenteral) in November 2023 (NCT05923008)
- 28 Jun 2023 Preclinical trials in Solid tumours in China (Parenteral) before June 2023